These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31398933)

  • 1. Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation.
    Varnai R; Koskinen LM; Mäntylä LE; Szabo I; FitzGerald LM; Sipeky C
    Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31398933
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Kaikkonen E; Ettala O; Nikulainen I; Taimen P; Lehtinen I; Boström PJ; Kellokumpu-Lehtinen PL; Schleutker J
    Anticancer Res; 2019 Oct; 39(10):5353-5359. PubMed ID: 31570429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.
    Mayer MJ; Klotz LH; Venkateswaran V
    J Urol; 2017 Apr; 197(4):1068-1075. PubMed ID: 27984108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapy in metastatic castration resistant prostate cancer.].
    Rosino A; Ballester I; Tudela J; González-Billalabeitia E
    Arch Esp Urol; 2018 Sep; 71(8):676-684. PubMed ID: 30319127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
    Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
    Basset V; Flamand V; Crouzet S; Ploussard G
    Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
    Szarvas T; Sevcenco S; Módos O; Keresztes D; Nyirády P; Csizmarik A; Ristl R; Puhr M; Hoffmann MJ; Niedworok C; Hadaschik B; Maj-Hes A; Shariat SF; Kramer G
    BJU Int; 2018 Oct; 122(4):695-704. PubMed ID: 29802777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
    Fukuta F; Kitamura H; Yanase M; Taguchi K; Takahashi A; Kunishima Y; Miyake M; Adachi H; Itoh N; Hirose T; Takagi S; Miyao N; Matsukawa M; Shigyo M; Masumori N
    Jpn J Clin Oncol; 2015 Jul; 45(7):682-7. PubMed ID: 25862824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.
    Seyednasrollah F; Koestler DC; Wang T; Piccolo SR; Vega R; Greiner R; Fuchs C; Gofer E; Kumar L; Wolfinger RD; Kanigel Winner K; Bare C; Neto EC; Yu T; Shen L; Abdallah K; Norman T; Stolovitzky G; Soule HR; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Elo LL; Zhou FL; Guinney J; Costello JC;
    JCO Clin Cancer Inform; 2017 Nov; 1():1-15. PubMed ID: 30657384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
    Guinney J; Wang T; Laajala TD; Winner KK; Bare JC; Neto EC; Khan SA; Peddinti G; Airola A; Pahikkala T; Mirtti T; Yu T; Bot BM; Shen L; Abdallah K; Norman T; Friend S; Stolovitzky G; Soule H; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Xie Y; Aittokallio T; Zhou FL; Costello JC;
    Lancet Oncol; 2017 Jan; 18(1):132-142. PubMed ID: 27864015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
    Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
    Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
    Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
    Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer.
    Maia MC; Pereira AAL; Lage LV; Fraile NM; Vaisberg VV; Kudo G; Barroso-Sousa R; Bastos DA; Dzik C
    J Glob Oncol; 2018 Sep; 4():1-9. PubMed ID: 30241182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    Kosaka T; Hongo H; Oya M
    BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.
    Gourdin T
    Curr Opin Oncol; 2018 May; 30(3):159-164. PubMed ID: 29553949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer.
    Gyawali B; Koomulli-Parambil S; Iddawela M
    Crit Rev Oncol Hematol; 2016 Jun; 102():118-24. PubMed ID: 27157868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
    Puente J; González-Del-Alba A; Sala-Gonzalez N; Méndez-Vidal MJ; Pinto A; Rodríguez Á; Cuevas Sanz JM; Muñoz Del Toro JR; Useros Rodríguez E; García García-Porrero Á; Vázquez S
    BMC Cancer; 2019 Aug; 19(1):766. PubMed ID: 31382926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.